Loading
In triple-negative breast cancer that had already been through at least two treatments, the TROP2 antibody-drug conjugate sacituzumab govitecan roughly doubled the time patients lived compared with standard chemotherapy.
Open-label phase 3 trial of 529 patients with relapsed or refractory metastatic triple-negative breast cancer after two or more prior chemotherapy regimens, randomised to sacituzumab govitecan or single-agent chemotherapy (eribulin, vinorelbine, capecitabine or gemcitabine). The primary endpoint was PFS in the 468 patients without brain metastases.
Median PFS was 5.6 vs 1.7 months (HR 0.41) and median overall survival 12.1 vs 6.7 months (HR 0.48). It converted the 2020 accelerated approval into a full approval and was the first ADC to show a survival benefit in TNBC.
Sacituzumab govitecan is a standard second-line or later treatment for metastatic triple-negative breast cancer, roughly doubling survival compared with the chemotherapies it was tested against. Patients should expect neutropenia and diarrhoea, which are manageable with growth factor support and loperamide. Trials are now testing it earlier, in first-line combinations with pembrolizumab and after surgery for residual disease.
Shares ASCENT-03, Javier Cortés, A randomised trial of antibody-drug conjugate sequence in metastatic triple-negative breast cancer, TROP2.
Shares Aditya Bardia, ASCENT, Sara M. Tolaney, TROP2.
Shares ASCENT-03, TROP2 PET to choose and sequence TROP2 ADCs, ASCENT-04 / KEYNOTE-D19, ASCENT.
Shares Sara A. Hurvitz, Javier Cortés, Payload (ADC), Progression-free survival (PFS).
Shares Hope S. Rugo, TROP2, Gilead Sciences (incl. Kite), Sacituzumab govitecan.
Shares Aditya Bardia, Sara M. Tolaney, Progression-free survival (PFS), Overall survival (OS).
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Metastatic triple-negative breast cancer, Topoisomerase-I inhibitors (and ADC payloads).
Shares Hope S. Rugo, A randomised trial of antibody-drug conjugate sequence in metastatic triple-negative breast cancer, Progression-free survival (PFS), Overall survival (OS).